Akebia Therapeutics Inc.

NASDAQ:AKBA   3:59:57 PM EDT
2.57
-0.14 (-5.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)449.63M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$51.38 Million
Adjusted EPS-$0.31
See more estimates
10-Day MA$2.68
50-Day MA$2.85
200-Day MA$3.11
See more pivots

Akebia Therapeutics Inc. Stock, NASDAQ:AKBA

245 First Street, Suite 1400, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.871.2098
Number of Employees: 379

Description

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.